Drug Development in the Era of Artificial Intelligence: Very Near Yet Too Far
DOI:
https://doi.org/10.47611/jsrhs.v14i1.8566Keywords:
Target Validation, Lead Identification, Lead optimization, Study design, Precision medicineAbstract
Development of a new therapeutic compound from discovery to market approval remains a long journey involving decades of research and development (R&D) and costing approximately $161 million to $4.54 billion (Schlander et al., 2021). However, recent decades have witnessed unprecedented and contemporaneous progress in computational technology, engineering, material sciences, multi-omics and biochemistry. This progress presents a very exciting opportunity to accelerate biomedical research and efficiently translate the same to meaningful shortening the time to market for drugs urgently needed for diseases that represent a huge burden to people suffering from these diseases and society at large. This article presents a review of the key advances in computational technology, medical engineering, material sciences, and multi-omics that are enabling a paradigm shift in drug development through all its stages with a potential for meaningful acceleration to meet the present significant unmet need in multiple diseases.
Downloads
References or Bibliography
Neurosync (2022). Blog: Digital Health and CNS Trials: A Promising Future Together - NeuroSync. [online] NeuroSync. Available at: https://www.neurosync.health/2022/06/20/blog-digital-health-and-cns-trials-a-promising-future-together/ [Accessed 26 Sep. 2024].
Anna Grazia Monteduro, Rizzato, S., Giusi Caragnano, Trapani, A., Giannelli, G. and Maruccio, G. (2023). Organs-on-chips technologies – A guide from disease models to opportunities for drug development. 231, pp.115271–115271. doi:https://doi.org/10.1016/j.bios.2023.115271.
AstraZeneca (2023). The changing landscape of precision medicine. [online] www.astrazeneca.com. Available at: https://www.astrazeneca.com/what-science-can-do/topics/technologies/precision-medicine-history.html [Accessed 26 Sep. 2024].
BDG LifeSciences (2024). Introduction: Artificial Intelligence (AI) has emerged as a powerful tool in various fields, and one of its most promising applications is in precision medicine. Precision medicine aims to provide personalized healthcare by tailoring medical treatments to individual patients based on their unique ge. [online] Linkedin.com. Available at: https://www.linkedin.com/pulse/role-artificial-intelligence-precision-medicine-bdglifesciences-piv3c/ [Accessed 26 Sep. 2024].
Corbett, J. (2022). Council Post: The Fallacy And Future Of Preclinical Drug Development. [online] Forbes. Available at: https://www.forbes.com/sites/forbestechcouncil/2022/05/26/the-fallacy-and-future-of-preclinical-drug-development/ [Accessed 8 Aug. 2024].
Glassman, P.M. and Balthasar, J.P. (2019). Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development. Drug Metabolism and Pharmacokinetics, [online] 34(1), pp.3–13. doi:https://doi.org/10.1016/j.dmpk.2018.11.002.
Gyan Consulting (2023). Preclinical drug development is a crucial stage in the journey of bringing a new medication to market. It involves a series of rigorous scientific evaluations and tests to determine a drug candidate’s safety, efficacy, and potential therapeutic benefits. [online] Linkedin.com. Available at: https://www.linkedin.com/pulse/challenges-preclinical-drug-development-how-overcome-them/ [Accessed 8 Aug. 2024].
Huang, W., Percie du Sert, N., Vollert, J. and Rice, A.S.C. (2019). General Principles of Preclinical Study Design. Good Research Practice in Non-Clinical Pharmacology and Biomedicine, 257, pp.55–69. doi:https://doi.org/10.1007/164_2019_277.
Hughes, J., Rees, S., Kalindjian, S. and Philpott, K. (2011). Principles of Early Drug Discovery. British Journal of Pharmacology, [online] 162(6), pp.1239–1249. doi:https://doi.org/10.1111/j.1476-5381.2010.01127.x.
Kaizer, A.M., Belli, H.M., Ma, Z., Nicklawsky, A.G., Roberts, S.C., Wild, J., Wogu, A.F., Xiao, M. and Sabo, R.T. (2023). Recent innovations in adaptive trial designs: A review of design opportunities in translational research. Journal of Clinical and Translational Science, 7(1). doi:https://doi.org/10.1017/cts.2023.537.
Lo, C. (2016). US Precision Medicine Initiative gears up for a massive e-health drive. [online] Pharmaceutical Technology. Available at: https://www.pharmaceutical-technology.com/features/featureus-precision-medicine-initiative-gears-up-for-a-massive-e-health-drive-5001799/ [Accessed 26 Sep. 2024].
Loewa, A., Feng, J.J. and Hedtrich, S. (2023). Human disease models in drug development. Nature Reviews Bioengineering, [online] 1(8), pp.545–559. doi:https://doi.org/10.1038/s44222-023-00063-3.
Lu, C.Y., Terry, V. and Thomas, D.M. (2023). Precision medicine: affording the successes of science. npj Precision Oncology, 7(1). doi:https://doi.org/10.1038/s41698-022-00343-y.
Mahalmani, V.M., Prakash, A. and Bikash Medhi (2023). Do alternatives to animal experimentation replace preclinical research? PubMed, [online] 55(2), pp.71–75. doi:https://doi.org/10.4103/ijp.ijp_223_23.
McDonald, E.R., de Weck, A., Schlabach, M.R., Billy, E., Mavrakis, K.J., Hoffman, G.R., Belur, D., Castelletti, D., Frias, E., Gampa, K., Golji, J., Kao, I., Li, L., Megel, P., Perkins, T.A., Ramadan, N., Ruddy, D.A., Silver, S.J., Sovath, S. and Stump, M. (2017). Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening. Cell, 170(3), pp.577-592.e10. doi:https://doi.org/10.1016/j.cell.2017.07.005.
National Institute on Aging (2023). What Are Clinical Trials and Studies? [online] National Institute on Aging. Available at: https://www.nia.nih.gov/health/clinical-trials-and-studies/what-are-clinical-trials-and-studies [Accessed 24 Jul. 2024].
Personalized Medicine Coalition (PMC) (n.d.). PERSONALIZED MEDICINE AT FDA. [online] Available at: https://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/PM_at_FDA_A_Progress_and_Outlook_Report.pdf.
Pfizer (n.d.). Precision Medicine Drug Development: What it is & How it Works. [online] www.pfizer.com. Available at: https://www.pfizer.com/science/innovation/precision-medicine#:~:text=Precision%20medicine%20relies%20on%20the [Accessed 26 Sep. 2024].
Pharmaceutical Technology (2020). Precision medicine in 2020: what barriers remain for drug developers? [online] Pharmaceutical Technology. Available at: https://www.pharmaceutical-technology.com/features/precision-medicine-2020/ [Accessed 26 Sep. 2024].
Smith, I., Greenside, P.G., Natoli, T., Lahr, D.L., Wadden, D., Tirosh, I., Narayan, R., Root, D.E., Golub, T.R., Subramanian, A. and Doench, J.G. (2017). Evaluation of RNAi and CRISPR technologies by large-scale gene expression profiling in the Connectivity Map. PLOS Biology, [online] 15(11), p.e2003213. doi:https://doi.org/10.1371/journal.pbio.2003213.
Spreafico, R., Soriaga, L.B., Grosse, J., Virgin, H.W. and Telenti, A. (2020). Advances in Genomics for Drug Development. Genes, [online] 11(8), p.942. doi:https://doi.org/10.3390/genes11080942.
Srivatsan, S.R., McFaline-Figueroa, J.L., Ramani, V., Saunders, L., Cao, J., Packer, J., Pliner, H.A., Jackson, D.L., Daza, R.M., Christiansen, L., Zhang, F., Steemers, F., Shendure, J. and Trapnell, C. (2019). Massively multiplex chemical transcriptomics at single-cell resolution. Science, 367(6473), pp.45–51. doi:https://doi.org/10.1126/science.aax6234.
The Humane Society of United States (2023). Disappointing National Academies study largely fails animals and people | The Humane Society of the United States. [online] www.humanesociety.org. Available at: https://www.humanesociety.org/news/disappointing-national-academies-study-largely-fails-animals-and-people#:~:text=Close%20to%2090%25%20of%20drugs [Accessed 8 Aug. 2024].
ThermoFisher Scientific (n.d.). Drug Discovery and Development Process. [online] PPD Inc. Available at: https://www.ppd.com/what-is-a-cro/drug-discovery-and-development/ [Accessed 24 Jul. 2024].
Tran, A., Wang, A., Mickaill, J., Strbenac, D., Larance, M., Vernon, S.T., Grieve, S.M., Figtree, G.A., Patrick, E. and Yang, J.Y.H. (2024). Construction and optimization of multi-platform precision pathways for precision medicine. Scientific Reports, [online] 14(1). doi:https://doi.org/10.1038/s41598-024-54517-8.
UCDavis (n.d.). What is Precision Medicine. [online] health.ucdavis.edu. Available at: https://health.ucdavis.edu/precision-medicine/what-is-precision-medicine.html#:~:text=Precision%20medicine%20is%20the%20intersection [Accessed 26 Sep. 2024].
Wouters, O.J., McKee, M. and Luyten, J. (2020). Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA, [online] 323(9), p.844. doi:https://doi.org/10.1001/jama.2020.1166.
Yamaguchi, S., Kaneko, M. and Narukawa, M. (2021). Approval success rates of drug candidates based on target, action, modality, application, and their combinations. Clinical and Translational Science, [online] 14(3), pp.1113–1122. doi:https://doi.org/10.1111/cts.12980.
Published
How to Cite
Issue
Section
Copyright (c) 2025 Ayushman Puri; Peng Zhao, Ph.D.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
